Creating a package that is suitable to get Bisantrene into the clinic on the big stage sooner rather than later, and not be frightened of the need for dilution to make this happen.
I'm hoping we get the new strategic update "swiftly"...
Given recent events, we should all agree that our number one priority should be getting Bisantrene into the clinic and into patients. Even if this means dilution...
Priority 1 - save patients.
Priority 2 - make money.
Ann: Appendix 4E & Annual Report, page-19
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.050(3.17%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $174.6K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2372 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 141 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |